Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Pegylated liposomal-doxorubicin + Trabectedin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Pegylated liposomal-doxorubicin||Doxil||ATI-0918|CAELYX||Chemotherapy - Anthracycline 12||Doxil (pegylated liposomal doxorubicin) is doxorubicin (intercalates into DNA, disrupting DNA replication) encapsulated, which within a liposome allows better penetration into tumors, decreases toxicity, and increases the period of effectiveness, and is FDA approved for ovarian cancer, AIDS-related Kaposi's sarcoma, and multiple myeloma (FDA.gov).|
|Trabectedin||Yondelis||ET-743||Chemotherapy - Alkylating 16||Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04887961||Phase II||Pegylated liposomal-doxorubicin + Trabectedin||Reprab Study: PLD + Trabectedin Rechallenge (MITO36)||Recruiting||ITA||0|